Overview

A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy

Status:
Completed
Trial end date:
2013-06-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether GSK2402968 is effective in the treatment of ambulant boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 skipping.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline